Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the Washington Post reported on Friday, citing documents from the Centers for Medicare and Medicaid Services.

A move to offer costly weight-loss drugs for obese Americans on Medicare and Medicaid may be in the works, but such a program may run into problems with voluntary participation and expense concerns.